Pfizer (PFE) Announces Positive Results from Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Go back to Pfizer (PFE) Announces Positive Results from Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis| Pfizer Inc. (NYSE: PFE) | Delayed: 27.66 +0.02 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.64 | 52 Week High | $37.39 | |||
| Open | $27.64 | 52 Week Low | $28.25 | |||
| Day High | $27.66 | P/E | 16.76 | |||
| Day Low | $27.34 | EPS | $1.65 | |||
| Volume | 75,587,710 | |||||
